Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intratumoral expression using a NFkB-based promoter enhances IL12 antitumor efficacy.
Garaulet G, Pérez-Chacon G, Alarcón H, Alfranca A, Mulero F, Martínez-Torrecuadrada J, Zapata JM, Rodríguez A. Garaulet G, et al. Among authors: zapata jm. Cancer Gene Ther. 2019 Jul;26(7-8):216-233. doi: 10.1038/s41417-018-0076-4. Epub 2019 Jan 9. Cancer Gene Ther. 2019. PMID: 30622324 Free article.
Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR.
Compte M, Harwood SL, Martínez-Torrecuadrada J, Perez-Chacon G, González-García P, Tapia-Galisteo A, Van Bergen En Henegouwen PMP, Sánchez A, Fabregat I, Sanz L, Zapata JM, Alvarez-Vallina L. Compte M, et al. Among authors: zapata jm. Front Immunol. 2021 Jan 7;11:614363. doi: 10.3389/fimmu.2020.614363. eCollection 2020. Front Immunol. 2021. PMID: 33488625 Free PMC article.
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.
Compte M, Harwood SL, Muñoz IG, Navarro R, Zonca M, Perez-Chacon G, Erce-Llamazares A, Merino N, Tapia-Galisteo A, Cuesta AM, Mikkelsen K, Caleiras E, Nuñez-Prado N, Aznar MA, Lykkemark S, Martínez-Torrecuadrada J, Melero I, Blanco FJ, Bernardino de la Serna J, Zapata JM, Sanz L, Alvarez-Vallina L. Compte M, et al. Among authors: zapata jm. Nat Commun. 2018 Nov 15;9(1):4809. doi: 10.1038/s41467-018-07195-w. Nat Commun. 2018. PMID: 30442944 Free PMC article.
CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110.
Domínguez JM, Pérez-Chacón G, Guillén MJ, Muñoz-Alonso MJ, Somovilla-Crespo B, Cibrián D, Acosta-Iborra B, Adrados M, Muñoz-Calleja C, Cuevas C, Sánchez-Madrid F, Avilés P, Zapata JM. Domínguez JM, et al. Among authors: zapata jm. J Hematol Oncol. 2020 Apr 7;13(1):32. doi: 10.1186/s13045-020-00865-7. J Hematol Oncol. 2020. PMID: 32264921 Free PMC article.
Editorial: Mouse Models of B Cell Malignancies.
Perez-Chacon G, Vincent-Fabert C, Zapata JM. Perez-Chacon G, et al. Among authors: zapata jm. Front Immunol. 2021 Oct 28;12:789901. doi: 10.3389/fimmu.2021.789901. eCollection 2021. Front Immunol. 2021. PMID: 34777400 Free PMC article. No abstract available.
99 results